New Biomarker Test Could Predict Outcome for Bladder Cancer Patients

	Tweet

A set of molecular biomarkers might better predict the recurrence of bladder cancer than conventional prognostic features such as the stage or grade of the malignancy at the time it is discovered, UT Southwestern Medical Center researchers have found.

Once a patient undergoes surgery for the removal of their bladder and lymph nodes - the standard treatment for muscle-invasive bladder cancer – researchers say a routine tissue analysis could easily test for the presence of mutated proteins, or biomarkers, that they found to help ascertain the chances that the cancer will return.

The findings, which researchers say could one day alter the postoperative treatment offered to patients who test positive for the mutated biomarkers, are available online and in an upcoming issue of The Lancet Oncology.

“Our goal is to identify patients who have a higher chance of cancer recurrence,” said Dr. Jose Karam, the study’s lead author and a medical resident at UT Southwestern. “If we can identify key biomarker alterations in these patients, we might be able to predict who will benefit from treatments such as chemotherapy.”

In the study, UT Southwestern scientists investigated the association of the proteins Bcl-2, caspase-3, P53 and survivin with the recurrence of cancer after surgery. The proteins are known to regulate apoptosis, or programmed cell death.

Apoptosis is a way for the body to safely dispose of dead cells, and it plays a role in preventing cancer. If cells don’t die when they are supposed to, they can continue dividing and change into a tumor.

“We are trying to identify tumors that are more aggressive and more likely to spread,” said Dr. Yair Lotan, assistant professor of urology at UT Southwestern and an author of the study. “Even after we’ve removed a diseased bladder and lymph nodes from a patient, more than 20 percent of patients have disease elsewhere in their body.”

Researchers collected archival tissue from 226 patients who underwent surgery for bladder cancer – the fourth most common cancer in men and the ninth most common cancer in women – between January 1987 and December 2002. They tested the tissue for the protein biomarkers and found that patients who showed mutations in all four biomarkers had a significantly increased rate of mortality from cancer after surgery. Patients who showed no mutations in the four biomarkers had a 90 percent chance of survival at five years compared to less than 20 percent if they had four mutated markers.

Dr. Shahrokh Shariat, the study’s senior author and a urology resident at UT Southwestern, said the findings suggest that mutations in the biomarkers indicate a malfunction in programmed cell death, leading to increased chances of cancer recurrence and mortality.

Dr. Karam noted that while the findings are still preliminary and need to be scientifically validated before being applied in the clinic, the results could change the treatment patients receive.

“Patients who have alterations on all four biomarkers might benefit from adjuvant chemotherapy even if the cancer appears to be confined to their bladder.

Otherwise, their chances for survival are likely to be poor,” said Dr. Karam. “Likewise, those who show none of the biomarkers might not need unnecessary chemotherapy.”

Other UT Southwestern researchers involved in the study were Dr. Arthur Sagalowsky, professor of urology and surgery; Dr. Claus G. Roehrborn, chairman of urology; Dr. Shahrokh F. Shariat, medical resident; and Dr. Raheela Ashfaq, professor of pathology. Researchers from the University of Montreal also participated.

The study was supported by the National Institutes of Health and the Austrian Programme for Advanced Research and Technology.

About UT Southwestern Medical Center

UT Southwestern Medical Center, one of the premier medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education. Its more than 1,400 full-time faculty members – including four active Nobel Prize winners, more than any other medical school in the world – are responsible for groundbreaking medical advances and are committed to translating science-driven research quickly to new clinical treatments. UT Southwestern physicians provide medical care in 40 specialties to nearly 89,000 hospitalized patients and oversee 2.1 million outpatient visits a year.

The UT Southwestern Harold C. Simmons Comprehensive Cancer Center combines the highest standards of individual care with innovative programs for cancer diagnosis, treatment and prevention based on UT Southwestern’s internationally recognized research coupled with the most sophisticated equipment and advanced technologies available. The expertise of the physicians in the Simmons Cancer Center extends to virtually every cancer in every age group, from breast, urologic, gynecologic, lung, gastrointestinal, head and neck, brain, and skin to lymphomas, leukemia, and marrow transplantation.

Source: UT Southwestern Medical Center

RELATED STORIES:
Consumption of Cultured Milk Products May Reduce Bladder Cancer Risk   Brochure Helps Patients Understand Treatments for Bladder Cancer   Protein Key to Bladder Cancer Spread, Potential Drug Target   Stanford computer algorithm used to identify bladder cancer marker   Meat, Especially If It’s Well Done, May Increase Risk of Bladder Cancer   Less bladder cancer in frequent painkiller users   Delaying bladder cancer surgery increases mortality   Arsenic cancer risk still high decades later in Chile region   Retired firefighters could be at increased risk for developing bladder cancer   Bladder cancer patients rarely receive recommended care   Home urine testing cuts bladder cancer deaths   Extract of broccoli sprouts may protect against bladder cancer   Urinary tract cancer associated with Chinese herbal products containing aristolochic acid   UT Southwestern researchers investigate high-risk populations for bladder-cancer screenings   Women in nursing homes often have bladder problems   Scientists find one reason why bladder cancer hits more men   AUA releases new guidelines on non-muscle invasive bladder cancer   New treatment option studied for bladder cancer   MDCT Shows Potential for Detecting Bladder Cancer Without Surgery or Contrast   Gene test shows which bladder cancer patients may have cancer spread   Sales jobs tied to bladder cancer risk   New made-in-Canada therapy for bladder cancer shows promising results

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]